Ascendis Pharma A/S, a clinical stage biotechnology company focused on creating drug candidates by improving existing drugs, recently announced results from its Phase 1 single ascending dose trial of TransCon Treprostinil, which produced a dose-dependent increase in plasma treprostinil levels. However, results from the study showed that the tolerability of treprostinil…

Findings from a recent study published in the Annals of Cardiac Anaesthesia determined that a multidisciplinary approach is key to the successful management of pregnant patients with Pulmonary Hypertension (PH). According to the study, secondary PH results in higher morbidity and mortality, and in particular the…

Researchers at the University of Glasgow and Glasgow Caledonian University in the United Kingdom published in the journal Cardiovascular Research findings revealing that that a specific receptor of the hormone estrogen is involved in the development of pulmonary hypertension. The findings may offer new insights into why…

According to a new paper, “Pulmonary hypertension and hepatic cirrhosis,” published in the Spanish-language journal, Revista Clinica Espanola, pulmonary hypertension (PH) occurs frequently in people with hepatic cirrhosis. There are various ways in which hepatic cirrhosis can be caused by PH, but the most common occurrence is something…

A new study led by researchers at Chengdu Women’s and Children’s Central Hospital in China revealed that angiotensin II interferes with the expression of collagen and specific proteins important in pulmonary hypertension pathology, suggesting a potential new therapeutic target. The study was published in the journal Genetics and…

Long-term results for the GRIPHON trial are in. According to a presentation made at the 35th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, selexipag (otherwise known as Uptravi® from Actelion) effectively treats patients with pulmonary arterial…

Serodus ASA recently announced that the company has filed a provisional patent application with the United Kingdom patent office for its experimental SER100 therapy, which will begin development for treatment of Pulmonary Hypertension. “We are pleased to introduce a new indication for one of our drug candidates. SER100 will now also be…

In a new study entitled “Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway,” the authors report on the beneficial effects of salidroside in treating hypoxia-induced pulmonary arterial hypertension by decreasing arterial remodeling and promoting pulmonary arterial smooth muscle cells apoptosis. The study was…

In a study titled “Increased prevalence of EPAS1 variant in cattle with high-altitude pulmonary hypertension,” researchers discovered two genetic variants responsible for brisket disease in cattle that may provide clues to human conditions associated with pulmonary hypertension. The study was published in the journal Nature Communications. High-altitude…

Results from a recent study published in the journal Respirology showed that an early decline in 6-minute walk test (6MWT) distance predicts deterioration of disease condition in patients with pulmonary arterial hypertension (PAH). The findings could provide new insights into effectively diagnosing and treating the disease using…

The Pulmonary Hypertension Association (PHA) is initiating a new social network, called myPHA, which was designed particularly for patients who suffer from pulmonary hypertension (PH). The resource was created to resemble a one-stop-shop virtual home, in which patients can interact with each other, as well…

Recent work in preclinical models suggests that signaling via the pro-angiogenic and pro-inflammatory cytokine, CXCL12 (SDF-1), plays an important pathogenic role in pulmonary hypertension (PH). Now a research team found that elevated concentrations of circulating CXCL12α predicts poorer survival in patients with Pulmonary Arterial Hypertension (PAH) and…